Navigation Links
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
Date:2/5/2009

/p>

Study Background

This multicenter, open-label phase I/II study was designed to determine the recommended dose, cardiac safety and antitumor activity of nonpegylated liposomal doxorubicin, paclitaxel and trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) or metastatic breast cancer (MBC).

Sixty-nine adult patients from Spain participated, 15 in the dose escalating part and 54 at the recommended phase II dose. Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC - and a baseline left ventricular ejection fraction (LVEF) > 50 percent - received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and nonpegylated liposomal doxorubicin every three weeks for six cycles. Overall response rate was defined as the total of complete response plus partial response. LVEF was monitored every 3 weeks for the first 18 weeks and every eight weeks thereafter.

Study Results

No case of symptomatic treatment-related cardiac failure was reported. A total of 12 patients (17%) developed asymptomatic minimal and reversible declines in LVEF. In eight of these patients, LVEF recovered to greater than or equal to 50% after a median time of nine weeks (range, 3-38 weeks). In the remaining patients, LVEF ranged from 44% to 49%.

The combination therapy was highly active and well-tolerated. The overall response rate, at the recommended phase II dose, was 98.1%: 29 patients achieved a complete response (53.7%) and 24 patients had a partial response (44.4%). This response rate ranks among the highest reported in HER-2-overexpressing breast cancer patients. The median time to progression was not reached in patients with locally advanced nonoperable breast cancer, while it exceeded 21 months in those with metastatic disease. The most common adverse events included alopecia (85.1%), mucosal inflammati
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
2. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
11. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... This ... industry.The report provides a basic overview of the industry including definitions, classifications, applications ... markets including development trends, competitive landscape analysis, and key regions development status. Development ...
(Date:7/27/2015)... Research presented at the 2015 AACC Annual Meeting & ... led to a fingerprick Ebola test becoming the first ... approval from the World Health Organization (WHO). This test ... West Africa by identifying suspected Ebola ... and treat these patients much faster than is currently ...
(Date:7/27/2015)... -- Junto Health, a company that helps major health ... technology solutions, today announced the launch of a partnership ... health care policy consulting. Working together with SPG, Junto ... process while, at the same time, they are also ... care finance and the delivery of health care services.   ...
(Date:7/25/2015)... (PRWEB) , ... July 25, 2015 , ... ... for its refractometer series. It precisely checks and adjusts the surface temperature of ... measurements. , In the pharmaceutical industry, data traceability and documentation are key requirements. ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4It’s T-Time for Refractometers: On-site Temperature Check Now Available 2
... and Fuel Cells Holds Growth and Profit PotentialPASADENA, ... stock alert issued last week on VIASPACE Inc. ... of VIASPACE,s alternative energy business and future growth ... Dr. Carl Kukkonen. Cohen Independent Research Group (CIRG) ...
... Biotechnology Value Fund, L.P. ("BVF") today announced that PROXY ... has recommended that shareholders vote for all BVF Proposals on ... Inc. (Nasdaq: AVGN ) to be held on ... circumstances we believe the dissidents (BVF) must clear a high ...
... Venture Capital Fund Will Invest in Biotech Start-up Companies ... GENEVA, March 23 Merck Serono, a division ... of ,Merck Serono Ventures, a strategic, corporate venture capital ... will support biotech start-up companies that have the potential ...
Cached Biology Technology:VIASPACE Inc. Alternative Energy Business Covered in Research Report 2VIASPACE Inc. Alternative Energy Business Covered in Research Report 3Leading Advisory Firm, PROXY Governance, Recommends Avigen Shareholders Vote on GOLD Card to Remove Incumbent Directors and Elect BVF's Stockholder-Oriented Nominees 2Merck Serono Launches Strategic Venture Capital Fund 2Merck Serono Launches Strategic Venture Capital Fund 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... Research Institute scientists has taken a significant step toward answering ... RNA enzymes that can replicate themselves without the help of ... indefinitely. The work was published on Thursday, January ... edition of the journal Science . In the ...
... Calif., January 9, 2009 -- Researchers at the ... that search algorithms used in digital communications can ... led by Giovanni Paternostro, M.D., Ph.D., was published ... PLoS Computational Biology . Using the stack ...
... unveil a novel "two-stage, approach for developing new energy ... emissions and create a cleaner economy during a policy ... York Ave. N.W. in Washington, D.C. , ... Mellon, the University of Minnesota, The Vermont Law School ...
Cached Biology News:Scripps scientists develop first examples of RNA that replicates itself indefinitely 2Scripps scientists develop first examples of RNA that replicates itself indefinitely 3Scripps scientists develop first examples of RNA that replicates itself indefinitely 4Digital communication technology helps clear path to personalized therapies 2Carnegie Mellon to unveil new sequestration plan 2
... centrifuge design and manufacturing, Thermo IEC introduces ... (refrigerated) general purpose models provide new conveniences ... Sample Preparation , The CL3 series will ... and has speed and accuracies to the ...
... Molecular Probes intensely fluorescent and highly ... for use in a variety of ... a strong signal. Unfortunately, protein- and ... that may cause them to bind ...
... The Centra-CL5R multi-purpose centrifuge offers both ... large assortment of rotor options, making ... laboratory applications., Maximum Versatility , ... xg) angle rotors or high-volume (4 x ...
... a fully licensed, high throughput, water bath thermal ... to 24 microplates. This equates to 9,216 reactions ... robotic arm rapidly transfers a basket of plates ... times that are considerably faster than those of ...
Biology Products: